(Q34179616)

31 July 2017

title

Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin (English)

1 reference

31 July 2017

1 reference

L K Teh

1

1 reference

31 July 2017

I M Langmia

2

1 reference

31 July 2017

M H Fazleen Haslinda

3

1 reference

31 July 2017

H A Ngow

4

1 reference

31 July 2017

M J Roziah

5

1 reference

31 July 2017

R Harun

6

1 reference

31 July 2017

Z A Zakaria

7

1 reference

31 July 2017

M Z Salleh

8

1 reference

31 July 2017

publication date

20 April 2011

1 reference

Journal of Clinical Pharmacy and Therapeutics

31 July 2017

published in

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

232-236

1 reference

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Evaluation of genetic factors for warfarin dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

Role of pharmacodiagnostic of CYP2C9 variants in the optimization of warfarin therapy in Malaysia: a 6-month follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01262.X

10.1111/J.1365-2710.2011.01262.X

21 January 2018

Identifiers

DOI

1 reference

release_4xbbujosorgbzcwffp6h36dbay

31 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4xbbujosorgbzcwffp6h36dbay

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference